Tiaki Therapeutics, with funding from the Dementia Discovery Fund (‘DDF’), is at the forefront of developing microglia-targeted therapeutics for the treatment of dementias. By harnessing new discoveries from academia, Tiaki is developing a platform to discover small molecule therapeutics which will restore microglial function in the aging brain.
About the Dementia Discovery Fund (DDF)
The DDF is a venture capital fund which invests in projects and companies to discover and develop novel, effective disease-modifying therapeutics for dementia. Seven leading pharmaceutical companies (GSK, Biogen, Lilly, Takeda, Pfizer, J&J, and Astex, a subsidiary of Otsuka), the UK’s Department of Health, and charity Alzheimer’s Research UK have invested in the DDF to date. Heads of Neuroscience and R&D represent these strategic investors on the DDF Scientific Advisory Board and work closely with DDF’s dedicated team of neuroscientists and experts to identify and evaluate novel approaches for the treatment of dementia.
- Barbara Tate, PhD Acting CEO
- Lauren Martens, PhD Director of Biology
- Kelley Larson Principal Scientist